Page last updated: 2024-08-25

bendamustine hydrochloride and lenalidomide

bendamustine hydrochloride has been researched along with lenalidomide in 50 studies

Research

Studies (50)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (2.00)29.6817
2010's36 (72.00)24.3611
2020's13 (26.00)2.80

Authors

AuthorsStudies
Lin, TS1
Dougherty, DW; Friedberg, JW1
Czuczman, MS; Leonard, JP; Williams, ME1
Cheson, BD; Friedberg, JW; Kahl, BS1
Rummel, M1
Cheson, BD1
Abbas, M; Agha, M; Boyiadzis, M; Burt, S; Dai, L; Kennedy, RC; Lentzsch, S; Mapara, MY; Normolle, D; O'Sullivan, A; Pregja, SL; Roodman, GD; Shuai, Y; Waas, J; Zonder, JA1
Moskowitz, AJ1
Ogura, M1
Alsina, M; Anderson, KC; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Illizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Kumar, R; Liedtke, M; Meredith, R; Raje, N; Schriber, J; Shead, DA; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Weber, D; Yahalom, J; Yunus, F1
Berardi Vilei, S; Berthod, G; Caspar, C; Eckhardt, K; Fischer, N; Hitz, F; Mey, U; Pabst, T; Zucca, E1
Akinleye, A; Wu, M; Zhu, X1
Al-Ali, HK; Beck, J; Edelmann, T; Hebenstreit, K; Heyn, S; Hoffmann, FA; Jäkel, N; Lange, T; Mohren, M; Niederwieser, D; Pönisch, W; Röhrborn, R; Schmalfeld, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T1
Giannotta, A; Guaragna, G; Mele, G; Melpignano, A; Quarta, G; Spina, A1
Cabanillas, F; Rivera-Rodriguez, N1
Argnani, L; Maglie, R; Pellegrini, C; Pileri, S; Zinzani, PL1
Nakaseko, C1
Aitchison, R; Blesing, N; Lau, IJ; Peniket, A; Rabin, N; Ramasamy, K; Roberts, P; Smith, D; Yong, K1
Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE1
Cheson, BD; Crawford, J1
Birgin, A; Buadi, FK; Duarte, L; Fiala, M; Gertz, MA; Krishnan, A; Kumar, SK; LaPlant, B; Laumann, K; Levy, J; Maharaj, M; Roy, V; Stockerl Goldstein, K; Vij, R; Zimmerman, T1
Berardi, M; Biagioli, T; Bosi, A; Brogi, M; Caldini, A; Nozzoli, C; Staderini, M; Terreni, A1
Bahlo, J; Bergmann, M; Binder, M; Böttcher, S; Cramer, P; Döhner, H; Dreyling, M; Eichhorst, B; Fink, AM; Fischer, K; Fischer, N; Gross-Ophoff, C; Hallek, M; Kluth, S; Kneba, M; Kreuzer, KA; Langerbeins, P; Maurer, C; Pflug, N; Rhein, C; Stilgenbauer, S; Tausch, E; Wendtner, CM1
Cheah, CY; Seymour, JF; Wang, ML1
Blank, J; Chang, JE; Eickhoff, J; Go, RS; Havighurst, T; Kahl, BS; Kim, K; Kirby-Slimp, R; Traynor, AM; Volk, LM; Weiss, M; Werndli, J1
Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S1
Freedman, AS; Jacobson, CA1
Berardi Vilei, S; Cairoli, A; Caspar, CB; Eckhardt, K; Enoiu, M; Fischer, N; Hitz, F; Krasniqi, F; Mach, N; Mey, U; Pabst, T; Rondeau, S; Rothermundt, C; Samaras, P; Schmidt, A; Zucca, E1
Hogan, JJ; Weiss, BM1
Badiali, S; Bari, A; Cocito, F; Corso, A; Gentile, M; Guarini, A; Marcheselli, L; Marcheselli, R; Mazzone, C; Mele, G; Minoia, C; Morabito, F; Musto, P; Palumbo, A; Pozzi, S; Ria, R; Rivolti, E; Sacchi, S; Vincelli, I1
Chan, TS; Khong, PL; Kwong, YL1
Arcari, A; Botto, B; Carmichael, J; Ceccarelli, M; Cellini, C; Drandi, D; Fanin, R; Ferranti, A; Ferrari, A; Ferrero, S; Ladetto, M; Liberati, AM; Minotto, C; Montechiarello, E; Musuraca, G; Patti, C; Pileri, SA; Salvi, F; Spina, M; Stelitano, C; Volpetti, S; Zaja, F1
Andrea, M; Beck, J; Becker, C; Bill, M; Edelmann, T; Gläser, D; Heyn, S; Hoffmann, FA; Jentzsch, M; Kragl, B; Kreibich, U; Lange, T; Mohren, M; Mügge, LO; Niederwieser, D; Pönisch, W; Schliwa, T; Schwarzer, A; Schwind, S; Uhlig, J; Winkelmann, C; Zehrfeld, T1
Campioni, M; DeCosta, L; Fink, L; Flinois, A; Gazzola, C; Gonzalez-McQuire, S; Leleu, H; Mennini, FS; Schoen, P; Yong, K1
Albertsson-Lindblad, A; Eskelund, CW; Geisler, CH; Grønbæk, K; Jerkeman, M; Kolstad, A; Laurell, A; Pedersen, LB; Räty, R1
Abramson, JS; Amrein, PC; Armand, P; Brown, JR; Davids, MS; Fisher, DC; Hochberg, EP; Neuberg, D; Soumerai, JD; Werner, L1
Advani, RH; Ansell, SM; Cescon, TP; Chang, JE; Cheema, PS; Dy, PA; Evens, AM; Gascoyne, RD; Habermann, TM; Hong, F; Kahl, BS; O'Brien, TE; Quon, A; Ranheim, EA; Winter, JN; Witzig, TE1
Cheson, BD; Nowakowski, G; Salles, G1
Albertsson-Lindblad, A; Eskelund, CW; Geisler, CH; Grønbaek, K; Jerkeman, M; Kolstad, A; Laurell, A; Lindberg, Å; Räty, R1
Cohen, JB; Romancik, JT1
Abraham, I; Calamia, M; McBride, A1
Cahill, KE; Smith, SM1
Chen, D; Chen, Y; Gao, J; Jia, Y; Tao, H; Wang, F; Wu, P; Zhou, Z1
Ambarkhane, S; Cordoba, R; Kapetanakis, V; Prawitz, T; Sabatelli, L; Sharma, A; Westley, T1
Gogia, A; Gupta, R; Kumar, L; Kumar, S; Malik, PS; Pathak, N; Prasad, CP; Sahoo, RK; Sharma, A1
Ambarkhane, S; Fleury, I; Greil, R; Hess, G; Huang, D; Joffe, E; Kim, K; Ku, M; Kurukulasuriya, NC; Marks, R; Mondello, P; Nowakowski, GS; Peters, A; Salles, G; Trotman, J; Waltl, EE; Winderlich, M; Yoon, DH; Zinzani, PL1
Frascione, PMM; Novo, M; Paruzzo, L; Poletto, S; Vitolo, U1
Kameoka, Y1
Cordoba, R; Fleury, I; Greil, R; Hess, G; Joffe, E; Kim, K; Ku, M; Kurukulasuriya, NC; Marks, R; Mondello, P; Nowakowski, GS; Peters, A; Sabatelli, L; Salles, G; Sporchia, A; Trotman, J; Waltl, EE; Winderlich, M; Yoon, DH; Zinzani, PL1

Reviews

18 review(s) available for bendamustine hydrochloride and lenalidomide

ArticleYear
Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.
    Clinical lymphoma & myeloma, 2008, Volume: 8 Suppl 4

    Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Flavonoids; Humans; Indoles; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Maximum Tolerated Dose; Nitrogen Mustard Compounds; Piperidines; Pyrroles; Thalidomide; Thionucleotides; Treatment Outcome

2008
Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy?
    Current hematologic malignancy reports, 2010, Volume: 5, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Lenalidomide; Nitrogen Mustard Compounds; Rituximab; Thalidomide; Vinblastine; Vinorelbine

2010
Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2010, Volume: 8 Suppl 6

    Topics: Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Pyrazines; Radioimmunotherapy; Rituximab; Thalidomide

2010
New agents in follicular lymphoma.
    Best practice & research. Clinical haematology, 2011, Volume: 24, Issue:2

    Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Follicular; Mice; Nitrogen Mustard Compounds; Phosphotransferases; Protein Kinase Inhibitors; Pyrazines; Recurrence; Remission Induction; Rituximab; Signal Transduction; Thalidomide; Tumor Microenvironment

2011
Novel agents in Hodgkin lymphoma.
    Current oncology reports, 2012, Volume: 14, Issue:5

    Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Brentuximab Vedotin; Everolimus; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Nitrogen Mustard Compounds; Protein Kinase Inhibitors; Sirolimus; Thalidomide

2012
Novel agents for chronic lymphocytic leukemia.
    Journal of hematology & oncology, 2013, May-16, Volume: 6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Thalidomide

2013
Recent advances in the management of mantle cell lymphoma.
    Current opinion in oncology, 2013, Volume: 25, Issue:6

    Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Child; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Patient Selection; Phosphatidylinositol 3-Kinases; Prognosis; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome

2013
[Treatment of transplant-eligible symptomatic multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Nitrogen Mustard Compounds; Pyrazines; Remission Induction; Thalidomide; Transplantation Conditioning

2014
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vincristine

2015
Mantle Cell Lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Apr-10, Volume: 34, Issue:11

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cytarabine; Drug Administration Schedule; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Staging; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Risk Factors; Rituximab; Thalidomide; Transplantation, Autologous

2016
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
    Vnitrni lekarstvi, 2016, Volume: 62, Issue:1

    Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Immunoglobulin M; Lenalidomide; Lymphatic Diseases; Neoplasm Recurrence, Local; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Rituximab; Splenomegaly; Thalidomide; Thrombocytopenia; Vincristine; Waldenstrom Macroglobulinemia

2016
Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma.
    Current hematologic malignancy reports, 2016, Volume: 11, Issue:3

    Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Combined Modality Therapy; Humans; Lenalidomide; Lymphoma, Follicular; Radioimmunotherapy; Rituximab; Stem Cell Transplantation; Thalidomide; Treatment Outcome

2016
Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.
    Clinical journal of the American Society of Nephrology : CJASN, 2016, 09-07, Volume: 11, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulins; Immunosuppressive Agents; Kidney Diseases; Lenalidomide; Melphalan; Oligopeptides; Paraproteinemias; Pentostatin; Rituximab; Thalidomide; Vidarabine

2016
Diffuse large B-cell lymphoma: new targets and novel therapies.
    Blood cancer journal, 2021, 04-05, Volume: 11, Issue:4

    Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Development; Humans; Immunoconjugates; Immunotherapy, Adoptive; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Molecular Targeted Therapy; Rituximab

2021
Sequencing of Novel Therapies for Mantle Cell Lymphoma.
    Current treatment options in oncology, 2021, 11-23, Volume: 22, Issue:12

    Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Glucocorticoids; Humans; Immunotherapy, Adoptive; Induction Chemotherapy; Lenalidomide; Lymphoma, Mantle-Cell; Proteasome Inhibitors; Protein Kinase Inhibitors; Receptors, Chimeric Antigen; Rituximab; Stem Cell Transplantation; Sulfonamides; Transplantation, Autologous; Transplantation, Homologous

2021
Follicular Lymphoma: a Focus on Current and Emerging Therapies
    Oncology (Williston Park, N.Y.), 2022, 02-08, Volume: 36, Issue:2

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Doxorubicin; Genetic Testing; Humans; Immune Checkpoint Inhibitors; Immunoconjugates; Immunotherapy, Adoptive; Lenalidomide; Lymphoma, Follicular; Maintenance Chemotherapy; Morpholines; Neoplasm Recurrence, Local; Phosphoinositide-3 Kinase Inhibitors; Prednisone; Pyridones; Rituximab; Sulfonamides; Vincristine

2022
Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
    Advances in therapy, 2022, Volume: 39, Issue:6

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Rituximab; Treatment Outcome

2022
Treatment strategies for patients with diffuse large B-cell lymphoma.
    Cancer treatment reviews, 2022, Volume: 110

    Topics: Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Receptors, Chimeric Antigen; Rituximab; Vincristine

2022

Trials

17 trial(s) available for bendamustine hydrochloride and lenalidomide

ArticleYear
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
    Blood, 2012, May-17, Volume: 119, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Recurrence; Thalidomide; Treatment Outcome

2012
[Current development of new drugs in malignant lymphoma].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat

2012
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
    Annals of hematology, 2013, Volume: 92, Issue:8

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Comorbidity; Dose-Response Relationship, Drug; Drug Eruptions; Fatigue; Female; Heart Diseases; Hematologic Diseases; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Nitrogen Mustard Compounds; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome

2013
Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.
    British journal of haematology, 2013, Volume: 162, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisolone; Recurrence; Thalidomide

2013
A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas.
    British journal of haematology, 2015, Volume: 169, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Thalidomide

2015
Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.
    American journal of hematology, 2015, Volume: 90, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide

2015
Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.
    European journal of haematology, 2016, Volume: 97, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chromosome Aberrations; Drug Administration Schedule; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Rituximab; Thalidomide; Treatment Outcome

2016
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
    British journal of haematology, 2016, Volume: 173, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Remission Induction; Rituximab; Thalidomide; Treatment Outcome

2016
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.
    British journal of haematology, 2016, Volume: 174, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lenalidomide; Lymphoma, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Thalidomide

2016
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome

2017
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.
    Haematologica, 2017, Volume: 102, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Retreatment; Rituximab; Thalidomide; Treatment Outcome

2017
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).
    Journal of cancer research and clinical oncology, 2017, Volume: 143, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prednisolone; Prospective Studies; Thalidomide

2017
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of
    Haematologica, 2018, Volume: 103, Issue:11

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Rituximab; Survival Rate; Tumor Suppressor Protein p53

2018
Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Administration Schedule; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Rituximab; Treatment Outcome

2019
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 09-01, Volume: 26, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lenalidomide; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Remission Induction; Rituximab; Young Adult

2020
Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience.
    Hematological oncology, 2022, Volume: 40, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Prognosis; Quality of Life; Rituximab; Survival Rate

2022
Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial.
    British journal of haematology, 2022, Volume: 198, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide

2022

Other Studies

15 other study(ies) available for bendamustine hydrochloride and lenalidomide

ArticleYear
Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion.
    Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:4

    Topics: Bendamustine Hydrochloride; Humans; Intracellular Signaling Peptides and Proteins; Lenalidomide; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Phosphoinositide-3 Kinase Inhibitors; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Thalidomide; TOR Serine-Threonine Kinases

2010
Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy.
    Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:5

    Topics: Adenine Nucleotides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bendamustine Hydrochloride; Clofarabine; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Phosphoinositide-3 Kinase Inhibitors; Rituximab; Thalidomide

2010
Multiple myeloma, version 1.2013.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Vorinostat

2013
Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Thalidomide; Treatment Outcome

2014
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
    Hematological oncology, 2016, Volume: 34, Issue:1

    Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Carmustine; Combined Modality Therapy; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Liposomes; Male; Melphalan; Polyethylene Glycols; Recurrence; Remission Induction; Salvage Therapy; Thalidomide; Transplantation, Autologous; Young Adult

2016
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
    Annals of hematology, 2015, Volume: 94, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Failure

2015
New patterns of relapse in multiple myeloma: a case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation.
    Clinical chemistry and laboratory medicine, 2016, Jun-01, Volume: 54, Issue:6

    Topics: Bence Jones Protein; Bendamustine Hydrochloride; Blood Protein Electrophoresis; Bortezomib; Dexamethasone; Humans; Immunoelectrophoresis; Immunoglobulin G; Immunoglobulin kappa-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Stem Cell Transplantation; Thalidomide

2016
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
    Prescrire international, 2016, Volume: 25, Issue:170

    Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine

2016
Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
    Annals of hematology, 2016, Volume: 95, Issue:11

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Burkitt Lymphoma; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Prednisone; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Vincristine

2016
Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
    Journal of medical economics, 2018, Volume: 21, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Female; France; Health Expenditures; Health Resources; Hospitalization; Humans; Italy; Lenalidomide; Male; Middle Aged; Models, Econometric; Multiple Myeloma; Retrospective Studies; Thalidomide; United Kingdom

2018
Economic evaluation of polatuzumab-bendamustine-rituximab
    Journal of medical economics, 2021, Volume: 24, Issue:sup1

    Topics: Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Cost-Benefit Analysis; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Rituximab

2021
Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report.
    Medicine, 2022, Mar-04, Volume: 101, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Gastroscopy; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome; Ultrasonography

2022
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 09-15, Volume: 28, Issue:18

    Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cohort Studies; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Oxaliplatin; Retrospective Studies; Rituximab; Treatment Outcome

2022
[Standard treatment and future perspectives for follicular lymphoma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2022, Volume: 63, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Quality of Life; Rituximab

2022
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large
    Annals of hematology, 2023, Volume: 102, Issue:7

    Topics: Adolescent; Adult; Bendamustine Hydrochloride; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Receptors, Chimeric Antigen; Retrospective Studies; Rituximab

2023